Pionyr Immunotherapeutics, Inc., a San Francisco, CA-based developer of antibody therapeutics that increase the body’s antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment, closed a $62m Series B funding round.
The round, which brings total funding to $72m, was led by New Enterprise Associates with participation from Sofinnova Ventures and Vida Ventures, and existing investors OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay Ventures.
Co-founded by Max Krummel, Ph.D., and Sachdev Sidhu, Ph.D., and led by Steven James, president and CEO, and Michel Streuli, Ph.D., senior vice president of research, Pionyr is exploiting novel target discovery and antibody generation platform technologies to create immuno-oncology therapeutics after checkpoint inhibitors and CAR-T.
The company’s initial approach, which it calls “Myeloid Tuning,” is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Pionyr has several preclinical antibody programs, two of which are nearing IND-enabling studies targeting solid tumors.